ARQULE INC
ARQL evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- derazantinib (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ARQL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
derazantinib (Phase 3)
Next Catalyst
—
Tracking 2 pipeline candidates · 2 clinical trials for ARQULE INC.
Similar companies
Run ARQULE INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARQULE INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is ARQULE INC's lead drug candidate?
ARQULE INC's most advanced tracked candidate is derazantinib (Phase 3) for Intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions.
Who is the CEO of ARQULE INC?
To Our Stockholders is the chief executive officer of ARQULE INC (ARQL).
What therapeutic areas does ARQULE INC focus on?
ARQULE INC develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.